Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALPS12 in Extensive Stage Small Cell Lung Cancer
NCT07107490Phase 1Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Oct 2025
- Primary completion
- Sep 2028
- Modality
- Bispecific Antibodies, T-cell Engagers, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of RG6538 in small cell lung cancer (SCLC), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Adverse events of ALPS12 at 42 months, Dose-limiting toxicities at 21 days and 3 more. Started Oct 2025; status: recruiting.
02
Drugs
RG6538
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07107490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07107490.